Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors.

Next Previous
Trial Profile

A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Breast cancer; Carcinoma; Fallopian tube cancer; Gastric cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Uveal melanoma
  • Focus Therapeutic Use
  • Sponsors Exelixis

Most Recent Events

  • 20 Oct 2017 Results assessing efficacy and tolerability of cabozantinib [XL 184] in patients with advanced solid tumours, with multi-cohorts of patients with metastatic hormone-refractory prostate cancer, ovarian cancer and breast cancer, were published in the European Journal of Cancer.
  • 26 Jul 2017 Results (N=70) of ovarian carcinoma cohort published in the European Journal of Cancer
  • 01 Mar 2017 Results from the hepatocellular carcinoma (n=41) cohort published in the Annals of Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top